Date: November 4-5, 2021 Online Streaming Lifescience and healthcare professionals across all department functions, and consultants are invited to attend DGE’s Advancing Diversity, Equity & Inclusion (“DEI”) In Pharma & Healthcare Conference, streaming live online November 4-5, 2021. The event is hosted by Dynamic Global Events (“DGE”), a global Life Science leader in organizing b2b events. The company supports the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. Igniting change and implementing new initiatives to create a more diverse and inclusive culture is paramount for the success of the life science and healthcare industries.  An inclusive organization positively impacts drug development and is a key enabler to improving diversity in clinical trials. The live streaming event serves as a networking arena to connect with prominent industry leaders at the forefront of their professions who are making a real difference in advancing their organization’s DEI initiatives. The event features thought leaders from pharmaceutical, biotechnology and medical device organizations of all sizes who will share innovative and successful strategies essential to addressing and advancing diversity and inclusion across all functions of the organization, and key insights to ensure a more diverse patient population in clinical trials The event highlights the need for medical affairs and clinical trial leaders to collaborate and strengthen their relationships with external stakeholders and gain a greater understanding of the challenges impacting diversity and inclusion in clinical trials. The robust agenda will provide attendees with a blueprint to strategically eliminate environmental barriers to diversity and inclusion and set their organization on a path to building and sustaining a culture of belonging—achieve and sustain DEI success. Themes include:

• Diversity In Clinical Trials & Drug Development Recruitment
• Retention & Workforce Management
• Emphasizing Equality And Inclusion In The Workplace
• Leadership & Career Development
• Measuring Current And Future DEI Progress

Session Highlights:

• Integrate D&I Into Talent Recruitment and Acquisition To Transform Your Workforce and
• Culture
• Rebuild DEI Strategy from a Functional Perspective
• Increase Diversity Among Leadership and Boards
• Develop Managers To Drive Engagement in DEI Initiatives
• Partner With External Stakeholders to Build Trust and Improve Clinical Trial Diversity

The Advancing Diversity, Equity and Inclusion in Pharma and Healthcare event will help you become a confident leader in this crucial business space – more important than ever and growing every year. Join us for 2-days of learning and networking to uncover how industry leaders across the life science and healthcare industries are building a culture of inclusivity and engagement. To learn more about the virtual event, please visit https://ibn.fm/V1E4b.

• Red White & Bloom Brands Inc. is a multi-state operator building steam within the cannabis market, particularly with recent growth developments in Florida and Michigan
• The company has obtained prequalification status for recreational use marijuana production in Michigan, and built out a production facility in Florida for edibles and other cannabis derivatives
• Florida is the nation’s third-largest market for cannabis and the largest for medical cannabis
• Red White & Bloom has named former congressman and current policy strategist Ryan Costello to its board to help drive the company’s plans for expansion

Cannabis multi-state operator and brand builder Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is positioning itself to become a market leader in the U.S. legal cannabis and hemp sector, announcing recently that it has welcomed former U.S. Congressman and now-public policy consultant Ryan Costello to its Board of Directors (https://ibn.fm/JV7YB). Costello, an experienced strategist who advises companies on matters before legislative and administrative agencies, has a wealth of knowledge on healthcare, energy, environmental, technology and transportation matters. He will “deepen the Company’s U.S.-based representation, which is key, as federal policy on cannabis shifts through many of the bills scheduled to reach the House of Representatives and Senate over the near future,” Chairman and CEO Brad Rogers stated in the news release. As an example of Red White & Bloom’s growing strength in its pursuit of stature as one of the top three multi-state cannabis operators active in the United States, the company announced earlier this month that it has built-out a new production facility to good manufacturing practice (“GMP”) specifications in Florida as part of an effort to capitalize on the growing cannabis derivative market there (https://ibn.fm/AY6Ru). Florida has become a battleground for U.S. multi-state operators, having established itself as the third-largest cannabis market in the country by annual sales and the largest market for medical marijuana, according to a recent Forbes report (https://ibn.fm/6QULM). “When we think about the future catalyst ahead in Florida, and we think about it going recreational and having the ability to sell to 130 million tourists every year, the opportunity is significant,” one company’s CEO told Forbes. “I don’t believe that there’s another market like it currently in the U.S.” The legalization of adult recreational use cannabis appears to be a few years away yet given the state Supreme Court’s response to the most recent legislative efforts, but advocates believe the momentum is building at a solid pace. Red White & Bloom has built a branded capsule and rosin line as well as a proprietary line of chocolates that the company expects to have out to medical patients by the end of the year. The Florida facility is a 4,800-square-foot standalone structure built to accommodate demand for edibles that grew from $5.3 million a month to over $13 million a month during the first half of the year, according to data provided by analysts at cannabis market watcher BDSA (https://ibn.fm/BNPf1). Elsewhere, Red White & Bloom received adult recreational use prequalification status in Michigan earlier this month as it works through the licensing provisions and associated rules in that state. “This now provides a clear path for us to fully execute on our strategy of being the house of brands and being great channel partners to all of our distribution points as well as our own planned flagship retail locations,” Rogers stated in the announcement (https://ibn.fm/iCUZ1). For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• NMRD has developed a proprietary technology that replaces traditional invasive methods of diagnosis and healthcare observation procedures
• Report notes that study participants are interested in using electronic methods to communicate more with their doctors between visits
• Better communication between patients and their healthcare providers impacts adherence to prescribed treatment

According to a report published in Dove Medical Press, communication between patients and their physicians has a notable impact on adherence to prescribed treatment and improved health care (https://ibn.fm/ZMYMQ). As a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, Nemaura Medical (NASDAQ: NMRD) pays special attention to essential information and research that impacts the successful implementation of its solutions. “Many patients are not satisfied with how their doctors communicate with them,” the report states. “Patients want to be more involved in planning their care and making decisions about their treatment. It is often difficult for patients to understand all the instructions from their doctors, especially when they receive too much information at one time. This is especially true for patients with chronic diseases, such as diabetes, where treatment is complicated and lifelong. Using electronic methods, such as smartphones, email, or text message, may help improve communication between patients and doctors.” These conclusions originate from a study titled “Mechanisms for improving diabetes patient–provider communication through optimal use of e-clinical technologies.” The study included a survey of 105 participants with type 2 diabetes, which indicated that most participants were interested in using electronic methods to communicate more with their doctors between visits. “Participants showed interest in using email to communicate with their doctor, and using a smartphone for medication reminders and scheduling doctor visits,” the report noted. “Patients need support and encouragement from their doctors, especially when dealing with lifelong complicated treatments, such as for type 2 diabetes. Our study shows that patients with type 2 diabetes are willing and interested in using electronic methods to increase communication with their doctors to manage their disease. This suggests that health care providers should consider using electronic methods to increase communication with the goal to improve health care.” These findings are particularly interesting to Nemaura, which has developed a proprietary technology that replaces traditional invasive methods of glucose monitoring that can be useful in disease management and diagnosis. NMRD’s BEAT(R) solution allows for continuous remote monitoring of chronic diseases and health conditions. Based on a world-class program initially developed at the Joslin Diabetes Center, BEAT is designed to help people with diabetes manage their condition and even potentially reverse type 2 diabetes using a combination of data from a wearable sensor and digital intervention and coaching. Nemaura’s BEAT is combined with the company’s proprietary sugarBEAT(R) sensor platform, which is the world’s first non-invasive daily-wear continuous glucose monitoring designed for use by people with both type 1 and type 2 diabetes as well as pre-diabetes, to trend glucose profiles. “Importantly, as a daily disposable adhesive skin-patch that sits on the surface of the skin, SugarBEAT is painless and versatile in terms of wear time,” said Nemaura CEO Dr. Faz Chowdhury (https://ibn.fm/GQZuV). “Due to the non-invasive nature of the sensor patch and connection to a rechargeable transmitter, SugarBEAT will allow users the freedom to decide when, and for how long to wear the patch.” This commitment to offering solutions designed to support patients in their treatment plans makes Nemaura distinctive — and that makes reports like the one published by Dove exciting. The company recently tweeted about the report (https://ibn.fm/qioHz), noting “the power of patient–provider communication. Optimal use of e-clinical technologies paves the way.” For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• “CBD may offer an option for treating different types of chronic pain,” reports Harvard article
• Topical CBD could help lower pain and inflammation due to arthritis, notes one study
• According to Simply Sonoma, the inflammation market represents a $100-billion opportunity and is one of three areas the company is working in

CBD, or cannabidiol, the second most prevalent of the active ingredients of cannabis, is gaining attention as a potential effective therapy for many uses, including inflammation. A recent article from Harvard Health Publishing notes the progress being made in that area (https://ibn.fm/xlwDr), an area that Simply Sonoma is heavily focused on. “CBD stands for cannabidiol,” the article stated. “It is the second most prevalent of the active ingredients of cannabis (marijuana). While CBD is an essential component of medical marijuana, it is derived directly from the hemp plant, which is a cousin of the marijuana plant. While CBD is a component of marijuana (one of hundreds), by itself it does not cause a ‘high.’ According to a report from the World Health Organization, ‘In humans, CBD exhibits no effects indicative of any abuse or dependence potential. . . . To date, there is no evidence of public health-related problems associated with the use of pure CBD.’ “CBD may offer an option for addressing different types of chronic pain. A study from the ‘European Journal of Pain’ showed, using an animal model, CBD applied on the skin could help lower pain and inflammation due to arthritis,” the article continued. “Another study demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain, two of the most difficult types of chronic pain to treat. More study in humans is needed in this area to substantiate the claims of CBD proponents about pain control.” According to Allied Market Research, the global pain management and inflammation market is expected to reach nearly $92 million dollars by 2027 and is one of three areas the company is working in; the other two are sleep aids, a $71-billion market, and the gut and probiotic health market, $54.77 billion in 2020. Simply Sonoma’s product development consists of clean, organic ingredients combined with a solar-first approach, resulting in as close to zero C02 emissions as possible. The company is currently working on an array of new products, including a joint/pain cream, as well as a nonalcoholic beverage made from grapes grown in Sonoma County. Simply Sonoma, a CBD company focused on building a reputation as a leader in plant-based medicinal health and beauty products. Specifically, Sonoma is developing broad-spectrum CBD products for therapeutic applications from a scientific perspective. Its products come from the farm rather than from a lab, with the goal of achieving fewer side effects and more efficacy for patients. The company is committed to incorporating published, science-based trials and research into the formulation and manufacture of its CBD offerings. “At Simply Sonoma, we strive to create the best organically grown medicinal products,” the company states. “We’re creating unique medicinal hemp strains that are alternatives and supplements to traditional, chemically manufactured therapies. We believe in all-natural, organically sun-grown, plant-based medicinals. We provide consumers with science-based education on CBD for disease and lifestyle needs. In our commitment to minimize our carbon footprint, we are powering our operations off the grid with solar.” Simply Sonoma is a different kind of natural company and looks forward to introducing its exceptional products to the consumer market. For more information, or to invest in Simply Sonoma, visit the company’s website at www.SimplySonoma.org. NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• RYAH Group is a digital healthcare analytics and technology company focused on developing tools that provide patients and doctors with the ability to accurately manage the intake in plant-based treatment
• The company recently revealed its participation at the Wall Street Reporter’s ‘Next Super Stock’ livestream conference held on September 23, 2021

RYAH Group (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. The company specializes in developing volume-control IoT devices to provide accurate volume control and management for various medical purposes. RYAH Group’s management recently revealed their attendance at the Wall Street Reporter’s “Next Super Stock” livestream conference, held on September 23, 2021  (https://ibn.fm/QtOfB). Wall Street Reporter’s Next Super Stock conference (https://ibn.fm/f5977) features select companies with major near-term catalysts in place to drive transformational growth (and stock appreciation) in the months ahead. Due to the ‘Next Super Stock’ conference’s track record showcasing companies which have enjoyed exponential increases in the weeks following the conference, hundreds of institutional investors habitually attend the meeting in anticipation of discovering the next big breakthrough. RYAH Group’s current product portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component, and the mobile application. The product line currently includes a Smart Dry-Herb Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage, and a Smart Liquid Dispensing Pen in the prototype stage. The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and pre-sets for temperatures and volumes. All of these features are customizable to individual needs and doctor recommendations. The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and heating element are completely IoT and controlled by RYAH’s proprietary smartphone applications, allowing on-demand scheduling and ‘boosting’ medicine release. RYAH’s Smart Liquid Dispensing Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect,’ enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. RYAH Group’s product suite of precision intake and volume management devices provides patients and medical practitioners with a practical toolkit to abide by volume control guidelines safely and accurately. In addition, detailed analytics provided by these RYAH devices help determine which intake volumes are working and what needs adjusting, along with accurately depicting a patient’s progress in their treatment. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• SRAX’s subsidiary BIGtoken to enter merger with Britepool, company providing identity resolution and verification services for advertisers and publishers
• SRAX expects transaction to benefit company’s shareholders with exchange of its shares for preferred shares with blockers at 4.99% and or 9.99%
• Combined entity boasts highly experienced management team, appears poised to provide next-gen privacy-focused solutions

SRAX (NASDAQ: SRAX), a financial technology company focused on improving communications between public companies and their investors, has recently announced the merger between its subsidiary Force Protection Video Equipment Corp. (“FPVD”), also known as BIGtoken, and Britepool, an identity resolution and verification service for advertisers and publishers (https://ibn.fm/g0QqH). As part of the transaction, SRAX is expected to exchange its approximately 150 billion shares for preferred shares with blockers at 4.99% and or 9.99%. This move will allow the company to recognize the value of the asset on its balance sheet without the need to consolidate BIGtoken’s operating results. It will also allow company’s investors to recognize the true operating performance of the Sequire, its software-as-a-service platform that unlocks data and insights for publicly traded companies. SRAX expects the transaction, which is awaiting regulatory approval, to benefit the company’s shareholders. “The movement of our position to a preferred share, which is currently worth a significant amount of money, will be very beneficial for our shareholders. The market will now be able to understand the true value that SRAX is generating on its own. We are currently exploring the best way to maximize the value of this asset for our shareholders,” said Christopher Miglino, Founder and CEO of SRAX. The merger is anticipated to close in approximately thirty days. The company is positive that the combined entity boasts strong leadership. “We are excited for the BIGtoken and BritePool teams to come together for this merger. The new combined management team is incredible,” added Miglino. The new company’s CEO will be David Moore, a digital advertising pioneer who was previously a partner in BritePool. George Stella, a veteran ad tech executive and a co-founder and president of BIGtoken, will continue to serve as the president after the merger (https://ibn.fm/DwCLE). As a company offering identity resolution and verification services for advertisers and publishers, BritePool provides precise, frequency-controlled identity targeting without third-party cookies. BIGtoken serves as a data marketplace that encourages users to share information in exchange for incentives. The combined entity will aim to provide the next evolution of privacy-focused solutions, with benefits for consumers and advertisers. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share
• Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs
• Lexaria is also investigating alternatives to smoked or inhaled nicotine delivery to avoid lung harm, expanding the potential of its technology
• DehydraTECH’s lymph system delivery method alternative to the digestive system provides more rapid bioavailability and fewer side effects, as well as the potential for better delivery across the blood-brain barrier
• The relatively low-cost technology has the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships

Oral drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) has drawn the attention of Zacks Small-Cap Research analysts, who have initiated coverage of Lexaria with a valuation of $15 per share because of the company’s patent portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption technology and the multiple potential uses of the technology. DehydraTECH pairs active pharmaceutical ingredients (“APIs”) with select long-chain fatty acid (“LCFAs”) oils that serve as carriers for the APIs though the lymphatic system, converting these compounds into ingestible formats that can be readily administered in capsules or liquid mixtures. Zacks focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators (https://ibn.fm/9XRDS). “Interest in using (DehydraTECH) extends across many categories beyond the primary pharmaceutical focus of the company from foods to beauty products and nutraceuticals, and across a range of formats from oral ingestible to oral buccal/sublingual to topical products,” Zacks notes in a news release issued Sept. 23 (https://ibn.fm/3FTTE). But thus far, Lexaria’s testing has focused on potential uses of DehydraTECH in treating high blood pressure (hypertension) in combination with cannabidiol (“CBD”), as well as in battling viruses through combination with such antivirals as remdesivir and colchicine and in providing alternatives to tobacco smoking through nicotine replacement therapy oral pouches. Clinical and preclinical studies have advanced Lexaria’s API toward commercialization in these areas, but DehydraTECH is already being used in CBD-based nutraceutical products distributed through retailers such as Albertson’s, Safeway and Hudson News stores. Zacks notes the potential market reach of Lexaria’s technology if regulatory-approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances. Lexaria’s use of the lymphatic system for bioavailability allows APIs to achieve more rapid delivery to the circulatory system and bypass the liver’s filtration mechanism, which digested medicines would normally be subject to. DehydraTECH’s lymph vessel delivery approach also has several advantages over digested medicines by decreasing concerns about taste, improving neurological delivery across the blood brain barrier, reducing the amount of drugs needed for usefulness, and decreasing the risk of side effects. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” CEO Chris Bunka said of the company’s brand partnerships earlier this summer (https://ibn.fm/PfLMa). “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.” For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Lobeline is Los Angeles-based with reach that extends from California to New York, Chicago, and Canada
• Fan Pass has released version 2.0, and continues the implementation of the Company’s growth strategy
• Artist Pro Services fuel this growth strategy with the inclusion of custom logo, merchandise and promotional designs

To help facilitate its Fan Pass live streaming artist platform’s growth strategy and brand-building efforts, mobile technology and marketing company Friendable (OTC: FDBL) announced that it was contracting a new public relations and digital partner, Lobeline Communications. The addition of Lobeline will help provide more exposure to what Fan Pass has to offer artists and fans alike (https://ibn.fm/bUJkO). Lobeline was founded by Phil Lobel, a former concert promoter, and serves the entertainment industry and music-related clients with PR, social media, and influencer marketing campaigns. Lobeline’s primary location is in Los Angeles, California, with additional offices reaching San Francisco, New York, Chicago, and Toronto, which can help extend the reach of Fan Pass across the country and international borders. The Fan Pass platform was founded by Robert A. Rositano Jr. (“CEO”) and his brother Dean Rositano (“CTO”) in July 2020. Together, they wanted to provide a virtual stage for musicians and their fans to come together. Since the original launch, Fan Pass has released version 2.0 of their new mobile and desktop applications, upgraded the experience for both artists and fans, and is continuing to move forward with their artist and fan acquisition outreach and monthly promotional contests that pay the artist to perform. According to Robert A. Rositano, the addition of Lobeline is a step in the right direction for Fan Pass, and the execution of the plan previously commenced. “We feel Fan Pass has secured the absolute correct partner for the Company’s growing needs in this entertainment sector and will continue adding to what is already a very talented and diverse team as we look to take advantage of several existing and new opportunities that we are currently engaged in. Our team is excited about these next stages of growth and expansion,” he explained. Fan Pass offers artists multiple avenues to earn revenue, including a piece of the monthly subscription fee that fans pay to access their favorite artist’s content, merchandise, and exclusive events. Artists have the tools they need to create, stream, and promote their art using the streaming gear and other services available in a one-of-a-kind Artist Pro Services shop. Fan Pass Artist Pro services offer artists unique tools to promote their music and brand. These services include artist/band logo, merchandise, and marketing designs. Each comes with three tiers to choose from and ranges in pricing from just under $50 to $400 depending on the level of services needed. The process is easy – artists fill out the form in the Pro-Services section, designers create mock-ups for the artist to review, and once the changes have been finalized, the artist approves the final graphics. In the future, Fan Pass also plans to add non-fungible tokens (“NFTs”), increasing the revenue opportunities of the artists currently on the platform. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• InnerScope Hearing Technologies is a direct-to-consumer manufacturer, distributor, and retailer of hearing aids and assorted hearing-related products
• The White House has recently published initiatives designed to de-regulate the hearing aid market, including allowing hearing aids to be purchased over the counter as well as negating the need for the devices to be prescribed by a medical professional
• InnerScope has introduced a series of free, self-administered hearing screening kiosks which can help consumers identify hearing loss and the severity of their hearing loss as well as the type of loss, and subsequently, recommend the best hearing aid for their particular case
• InnerScope has recently launched its product range on FSAstore.com, HSAstore.com, and WellDeservedHealth.com, as well as its own e-commerce site, MyHearIQ.com.

Although approximately 28.8 million Americans could benefit from wearing hearing aids today, fewer than 16 percent have ever used them. In fact, studies have shown that most people wait nearly 15 years from the time they know they have hearing loss until they actually purchase their first hearing aids – often citing elevated device prices as a barrier to purchase (https://ibn.fm/xFSCM), even though untreated hearing loss could be a precursor to more significant mental health problems, including depression, social isolation, and serving as an early indicator of Alzheimer’s disease. InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), as well as various hearing-related treatments, has sought to target this issue, thereby improving the quality of life of the 70 million people in North America and the 1.5 billion people worldwide suffering from hearing-related issues. On July 9, 2021, the White House published a new directive on promoting competition within the American economy through the planned promulgation of initiatives such as allowing hearing aids to be sold over the counter at drug stores and reducing the cost of hearing aids from the current average of $5,000 per pair (https://ibn.fm/bqJM0). InnerScope has positioned itself to benefit from the potential shift in regulations through its innovative in-store free self-check hearing screening kiosks (“Hearing Kiosks”) and a customer monthly subscription model, which can help consumers purchase superior quality hearing aids at an affordable monthly price. InnerScope has started its national rollout of Hearing Kiosks at a string of national pharmacy chains, big-box retailers, and grocery chains across the country. The Hearing Kiosks are equipped with the world’s first ‘hearing triage’ artificial intelligence pattern recognition software, which has a unique ability to classify both the degree of hearing loss and the type of loss. Following detection, the Hearing Kiosks can then make recommendations for one of InnerScope’s hearing devices and advise whether the consumer should seek further attention from a medical professional should follow-up testing be necessary. In addition to providing free, self-administering hearing screening kiosks, InnerScope has also made hearing aids more accessible to the public by recently launching their product range on FSAstore.com, HSAstore.com, and WellDeservedHealth.com for the 70 million consumers currently enrolled in flexible spending accounts, health savings accounts, and employers’ health incentive programs. Moreover, the company has recently launched its dedicated online store, www.MyHearIQ.com enabling any customer with a smartphone to personalize each hearing device to their specific needs using an onboard in-ear custom-fit self-testing feature through the free HearIQ app ‎ offered at the apple app store hearIQ on the App Store (apple.com) and Google Play Store hearIQ – Apps on Google Play. InnerScope is operating at the vanguard of the hearing aid market, working towards shifting hearing health care away from traditional brick-and-mortar clinics and towards customers’ homes by providing a unique and affordable solution to resolve consumers’ hearing needs. With the global hearing aid market expected to reach $11.02 billion by 2028, representing an earnings growth CAGR of 7.4% over the 2021-2028 interim, InnerScope Hearing Technologies is poised to benefit from a rapidly expanding total addressable market while simultaneously gaining from the United States Government’s recent initiatives to promote competition and broaden customer choice within the sector. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.MyHearIQ.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• American Cannabis Partners has focused on the safety of shareholders’ investments from day one
• CEO brought the culture and story of the Jamaican people to influence the US cannabis industry
• ACP seeks to improve the lives of individuals through cannabis and business in all that it does

When it comes to building steady growth and reducing risk, Stephen Jordan, CEO of American Cannabis Partners (“ACP”) focuses on “assets, assets, assets — and then build the operations out.” This is a rarity within the cannabis industry where most companies create a product first and if something happens where they are unable to make that product, they go under. ACP does business differently. The goal is to stay afloat, regardless of what happens regarding regulation changes in the cannabis industry. As a multi-state operator, it can pivot within the fluctuations of each state’s laws. The ability to liquidate, move and still survive was and is a founding strategy that allows it to protect its shareholders. The company’s ethics demonstrate “people before profit” at every step. From a strategic startup to maintained relationships with growers in Jamaica and shareholders, ACP believes and practices social and emotional intelligence. As a fairly new industry, cannabis runs risks for both the companies and the shareholders who invest in them. ACP worked from day one to eliminate those risks for its shareholders by first raising capital and then investing that money into assets in cannabis-friendly states where there is population demand, agricultural zoning, and available licenses. The company does not go into debt to obtain these assets but is committed to remaining debt-free and cash-flow positive. Cost-effective measures are immediately put into place once the sale is complete in order to increase the market value of any real estate it has acquired. This is what gives the shareholder extra safety if the laws do suddenly change or if the industry bottoms out. As a cash-flow positive company, ACP will be able to liquidate, pivot and take care of its shareholders first. The shareholders aren’t the only people ACP is committed to. The people and culture of Jamaica won Jordan’s heart during a three-year tenure as the Director of Operations for a U.S. based company operating in the Jamaican cannabis space. The relationships and family he built in Jamaica impacted him greatly. When Jordan left, he knew that the U.S. cannabis space would benefit greatly from the Jamaican experience, so he brought it with him. “One of the greatest things about being in Jamaica is the happiness of the people,” said Jordan during a recent podcast appearance on Bell2Bell. “Even in the face of adversity, poverty, political turmoil, and everything else, they’re still happy people — constantly happy people. Cannabis is a big attribute to that.” It was the culture and the story that Jordan wanted to bring back with him, and he did with key employees such as Lead Grower Junior Gordon. Gordon is recognized as one of the top-ranked growers in the world. With a talented team, he monitors daily plant health to ensure optimal growth of high-quality, uniform plants. But it’s not just the people that Jordan brought back with him to grow ACP. The people of Jamaica and the growers have not been forgotten. ACP is a high-paying grower that works hard to maintain a positive and serious relationship with the people of Jamaica. It seeks to improve the lives of individuals through cannabis and business in all that it does. Three complementary business segments hold this multi-state cannabis company’s focus — real estate, acquisition and development of proprietary assets, and ongoing cultivation operations. An important goal for 2021 is to bring the website fully online to capitalize on the company’s revenue and on building solid relationships with its consumers. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP